Novavax/$NVAX
1D1W1MYTD1Y5YMAX
Capital at risk
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
- Ticker
- $NVAX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 749
- Headquarters
- Gaithersburg, United States
- Website
- www.novavax.com
Novavax Metrics
BasicAdvanced
$1.6B
-
-$1.52
2.42
-
Price and volume
Market cap
$1.6B
Beta
2.42
52-week high
$11.97
52-week low
$6.20
Average daily volume
5.1M
Financial strength
Current ratio
2.333
Quick ratio
2.233
Long term debt to equity
-1.537
Total debt to equity
-1.559
Interest coverage (TTM)
-5.20%
Profitability
EBITDA (TTM)
-101.552
Gross margin (TTM)
-2.56%
Net profit margin (TTM)
-59.87%
Operating margin (TTM)
-28.85%
Effective tax rate (TTM)
-0.98%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-6.51%
Return on equity (TTM)
323.66%
Valuation
Price to revenue (TTM)
3.944
Price to book
-8.64
Price to tangible book (TTM)
-5.43
Price to free cash flow (TTM)
-37.929
Free cash flow yield (TTM)
-2.64%
Free cash flow per share (TTM)
-0.264
Growth
Revenue change (TTM)
-61.64%
Earnings per share change (TTM)
-159.61%
3-year revenue growth (CAGR)
-36.25%
10-year revenue growth (CAGR)
36.01%
3-year earnings per share growth (CAGR)
-40.03%
10-year earnings per share growth (CAGR)
-22.68%
What the Analysts think about Novavax
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Analyst projections of the future price of Novavax stock.
Bulls say / Bears say
Approvals for the XFG-adapted Nuvaxovid in the US, EU and Japan support another royalty-earning season, while Sanofi expands marketing and launches in more markets. Novavax receives those royalties without carrying its own commercial infrastructure. (Novavax)
Matrix-M is developing into a broader licensing platform rather than a single-product asset. Pfizer has selected a first development field under a deal with up to $500 million in milestones, and Novavax says four top-10 pharmaceutical companies are working with its technology. (StockAnalysis)
The underlying COVID vaccine market remains weak: second-quarter revenue fell 76% year on year to $57 million. Novavax is therefore relying increasingly on licensing payments and cost cuts to offset weaker direct vaccine demand. (Reuters)
Novavax has handed lead commercial responsibility for Nuvaxovid in key markets to Sanofi, and its 2026 revenue framework excludes Sanofi sales, royalties and milestones because they depend on partner forecasts. This leaves visibility and control over a central revenue stream limited. (Novavax)
The non-COVID pipeline is still early and unproven: the C. difficile programme is only expected to enter clinical development as early as 2027, while oncology work is producing preclinical data. These programmes offer long-term optionality but little near-term product revenue. (Novavax, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Novavax Financial Performance
Revenues and expenses
Novavax Earnings Performance
Company profitability
Upcoming events
No upcoming events
Novavax News
AllArticlesVideos
Funds containing Novavax
AllUSDEURGBP
Fund name | Fund size | $NVAX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.16% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.16% |
iShares Healthcare Innovation£DRDR | £1B | 0.16% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.